Michel Vounatsos, Biogen CEO (Dina Rudick/The Boston Globe via Getty Images)

Bio­gen los­es an­oth­er bid to re­vive Tec­fidera patent as gener­ic keeps eat­ing in­to block­buster sales

When Bio­gen lost its ap­peal to re­vive a key patent for Tec­fidera last No­vem­ber, the big biotech filed for a re­hear­ing in a last-ditch ef­fort to re­store its crum­bling block­buster mul­ti­ple scle­ro­sis fran­chise.

Four months lat­er, the ap­peals court has re­ject­ed its re­quest.

The set­back leaves the Supreme Court as Bio­gen’s fi­nal re­sort if it still wants to block Vi­a­tris — for­mer­ly My­lan — from mar­ket­ing a Tec­fidera gener­ic, which has and is ex­pect­ed to se­ri­ous­ly eat in­to Tec­fidera sales.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.